Clinical Trial Update: A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial of an anti-CTLA-4 antibody in advanced synovial sarcoma was terminated with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Synovial Sarcoma

Drugs mentioned

• Anti-CTLA-4 antibody

Snippet

Sponsor: Ludwig Institute for Cancer Research | Conditions: Synovial Sarcoma | Phase 2 | Status: TERMINATED | Results posted: 2021-07-14